Kynamro
Active Ingredient(s): Mipomersen SodiumFDA Approved: * January 29, 2013
Pharm Company: * GENZYME CORP
Category: Cholesterol
Mipomersen (INN; trade name Kynamro) is a drug used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous injection. There is a serious risk of liver damage from this drug and it can only be prescribed in the context of a risk management plan. Contents 1 Indications 1.1 Pregnancy and lactation 2 Contraindications 3 Adverse effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacokinetics 6 Chemistry 7 History 8 References Indicati... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
